Related Experiment Video

Updated: Aug 12, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Are there special considerations relevant to trials of biologic agents?

V Strand1

  • 1Clinical Faculty, Division of Immunology, Stanford University School of Medicine, Palo Alto.

The Journal of Rheumatology. Supplement
|September 1, 1994
PubMed

Insights

Biologic agents show discrepancies between biological and clinical effects. Evaluating both short-term and long-term efficacy is crucial for disease-controlling antirheumatic therapy (DC-ART) classification.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Clinical Trials

Background:

  • Biologic agents target specific pathogenic pathways.
  • Discrepancies between biological and clinical effects of these agents are common.
  • Current disease-controlling antirheumatic therapy (DC-ART) classification emphasizes long-term efficacy.

Purpose of the Study:

  • To evaluate the necessity of assessing both biological and clinical effects of biologic agents in trials.
  • To address the challenges posed by the short-term benefit of biologic agents within the DC-ART framework.
  • To propose alternative classifications for biologic agents to meet DC-ART requirements.

Main Methods:

  • Review of existing trial methodologies for biologic agents.
  • Analysis of biological effect assessment for primary pathway influence.
  • Examination of clinical evaluation standards comparable to pharmacological agents.

Main Results:

  • Biological effects require assessment to validate proposed mechanisms and influences.
  • Clinical evaluation of biologic agents should align with pharmacological agent assessment standards.
  • Biologic agents generally demonstrate short-term benefits, challenging DC-ART requirements.

Conclusions:

  • Biologic agents may require a "remission induction" category.
  • Alternatively, long-term combination therapy with pharmaceuticals or other biologics can fulfill DC-ART criteria.
  • Integrated assessment of biological and clinical outcomes is essential for effective use of biologic agents.

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)04:11

A Video Protocol of a Randomized Controlled Clinical Trial - Electrochemotherapy of Cutaneous Metastases with Reduced Dose Bleomycin (BLESS Trial)

Published on: June 9, 2026

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...